Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.48 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.48 |
| ▸ | GGT1 | P19440 | 4/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6027700 | 0.97 | — | — | |
| SCHEMBL8244 | 0.97 | — | — | |
| SCHEMBL6028073 | 0.97 | — | — | |
| SCHEMBL28659265 | 0.95 | GRIK1 (0.58) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL30391170 | 0.95 | GRIK1 (0.58) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Phosphoric Acid SCHEMBL2150696 | 0.88 | GRIK1 (0.52) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL29098570 | 0.84 | GRIK1 (0.48) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL21447999 | 0.81 | SLC7A5 (0.58) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL874270 | 0.81 | SLC7A5 (0.58) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL877833 | 0.81 | SLC7A5 (0.58) | GRIK1SLC7A5GRIK2GRM1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 677 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20250325486-A1 | AMINOLEVULINIC ACID HYDROCHLORIDE FREEZE-DRIED FORMULATION AND PREPARATION METHOD THEREOF | ZHAOKE PHARMACEUTICAL (HEFEI) CO., LTD (CN) | 2025-10-23 | — | — | US | claimed |
| EP-4611815-A1 | PHOTODYNAMIC THERAPY METHODS | Sun Pharmaceutical Industries, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250275536-A1 | Antimicrobial Composition | KAMER, Patrick (CH) | 2025-09-04 | — | — | US | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| CN-222828959-U | Low-efficiency photodynamic hydrogel treatment device capable of automatically adjusting light intensity | 中国人民解放军陆军特色医学中心 | 2025-05-06 | — | — | CN | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| EP-4518653-A1 | ANTIMICROBIAL COMPOSITION | Kamer, Patrick (CH) | 2025-03-12 | — | — | EP | claimed |
| EP-4516291-A1 | AMINOLEVULINIC ACID HYDROCHLORIDE FREEZE-DRIED FORMULATION AND PREPARATION METHOD THEREFOR | Zhaoke Pharmaceutical (Hefei) Co., Ltd (CN) | 2025-03-05 | — | — | EP | claimed |
| CN-119546336-A | Allo-low immunity bionic nano vesicle for treating cancer | T·马尔科姆 | 2025-02-28 | — | — | CN | claimed |
| US-20160317831-A1 | METHOD FOR THE TREATMENT OF ACNE | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2016-11-03 | — | — | US | claimed |
| US-20160319368-A1 | A Method for Identification of Anti-HIV Human miRNA Mimics and miRNA Inhibitors and Anti-HIV Pharmaceutical Compounds | CSIR (ZA) | 2016-11-03 | — | — | US | claimed |
| EP-3084008-A2 | A METHOD FOR IDENTIFICATION OF ANTI-HIV HUMAN MIRNA MIMICS AND MIRNA INHIBITORS AND ANTI-HIV PHARMACEUTICAL COMPOUNDS | CSIR (ZA) | 2016-10-26 | — | — | EP | claimed |
| US-9387341-B2 | Method for the treatment of acne | DUSA PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | claimed |
| WO-2015092707-A2 | A METHOD FOR IDENTIFICATION OF ANTI-HIV HUMAN MIRNA MIMICS AND MIRNA INHIBITORS AND ANTI-HIV PHARMACEUTICAL COMPOUNDS | CSIR (ZA) | 2015-06-25 | — | — | WO | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-6863650-B1 | Endoscopic instrument for performing endoscopic procedures or examinations | KARL STORZ GMBH & CO. KG (DE) | 2005-03-08 | — | — | US | claimed |
| EP-0998239-B1 | ENDOSCOPIC INSTRUMENT FOR CARRYING OUT ENDOSCOPIC INTERVENTIONS OR EXAMINATIONS AND ENDOSCOPIC INSTRUMENTATION CONTAINING SUCH AN ENDOSCOPIC INSTRUMENT | STORZ KARL GMBH & CO KG (DE) | 2004-10-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325486-A1 | AMINOLEVULINIC ACID HYDROCHLORIDE FREEZE-DRIED FORMULATION AND PREPARATION METHOD THEREOF | ALAD, AASDHPPT, ABAT | PTGS1 3389/4885GRIK1 3583/4885SLC7A5 44/4885 |
| US-20250275536-A1 | Antimicrobial Composition | CUTA, POLR1C, PIK3C3 | PTGS1 3127/4885GRIK1 4358/4885SLC7A5 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.